Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
| 11.33 Delayed Data As of 3:59pm ET |  +0.72 / +6.79%Today’s Change | 6.25 Today|||52-Week Range 13.56 | +17.41% Year-to-Date |
Latest TEVA News | Press Releases
| Is Teva Pharmaceuticals a Safe Stock to Buy Now? Feb 21 / MotleyFool.com - Paid Partner Content | TEVA Stock Declines Despite Q4 Earnings and Sales Beat Feb 11 / Zacks.com - Paid Partner Content |
| 2 Stocks I'd Avoid at All Costs Feb 20 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 10.61 |
| Today’s open | 10.64 |
| Day’s range | 10.55 - 11.47 |
| Volume | 15,957,137 |
| Average volume (3 months) | 9,189,853 |
| Market cap | $12.2B |
Data as of 3:59pm ET, 02/24/2021
Growth & Valuation
| Earnings growth (last year) | -299.46% |
| Earnings growth (this year) | +1.83% |
| Earnings growth (next 5 years) | +4.03% |
| Revenue growth (last year) | -0.90% |
| P/E ratio | NM |
| Price/Sales | 0.63 |
| Price/Book | 1.22 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BBIOBridgeBio Pharma Inc | +1.58 | +2.40% |
| IMMBImmunotech Laborator... | 0.00 | 0.00% |
| ---- | ||
| BGNEBeigene Ltd | +2.10 | +0.63% |
Data as of 3:59pm ET, 02/24/2021
Financials
| Next reporting date | May 13, 2021 |
| EPS forecast (this quarter) | $0.59 |
| Annual revenue (last year) | $16.8B |
| Annual profit (last year) | -$4.0B |
| Net profit margin | -23.95% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Generic |
No executives to display |
Corporate headquarters Petach Tikva, Hamerkaz |
Forecasts
